NEW YORK, January 9, 2017 /PRNewswire/ --
For today, Stock-Callers.com scans the performances of four Biotech equities which are: ImmunoGen Inc. (NASDAQ: IMGN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), CEL-SCI Corp. (NYSEMKT: CVM), and Dipexium Pharmaceuticals Inc. (NASDAQ: DPRX). These companies are engaged in the controlled and deliberate manipulation of biological systems for the efficient manufacturing or processing of useful products. Learn more about these stocks by downloading their free report at:
Last Friday, shares in Massachusetts headquartered ImmunoGen Inc. ended the session 6.33% higher at $2.52. The stock recorded a trading volume of 3.45 million shares, which was above its three months average volume of 1.88 million shares. The Company's shares have advanced 27.27% in the last month and 23.53% since the start of this year. The stock is trading 33.45% above its 50-day moving average. Moreover, shares of ImmunoGen, which develops targeted anticancer therapeutics, have a Relative Strength Index (RSI) of 72.71.
On December 28th, 2016, ImmunoGen announced that results from the Phase 1 expansion cohort evaluating mirvetuximab soravtansine (IMGN853) in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer were published in the Journal of Clinical Oncology. The data demonstrate the potential clinical benefit of mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer. The Phase 1 expansion cohort enrolled 46 patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors were positive for FRα. Patients were dosed with mirvetuximab soravtansine once every three weeks. Mirvetuximab soravtansine demonstrated single-agent activity in the 46-patient cohort with a 26% confirmed response rate and median progression free survival (PFS) of 4.8 months. In a subset of 23 patients with low, medium or high FRα, who had received three or fewer prior lines of therapy, there was a 39% objective response rate (ORR) and median PFS of 6.7 months. The free research report on IMGN is available at:
California headquartered BioMarin Pharmaceutical Inc.'s stock gained 0.65%, to close the day at $86.85 with a total trading volume of 776,503 shares. The Company's shares have advanced 4.65% in the past month and 4.84% on an YTD basis. The stock is trading 2.02% above its 50-day moving average. Additionally, shares of BioMarin Pharma, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 57.12.
On January 08th, 2017, BioMarin Pharma announced an update to its positive interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. A total of nine patients with severe hemophilia A received a single dose of BMN 270, seven of whom have been treated at the highest dose of 6 x 1013 vg/kg. As of the December 09th, 2016 data cutoff, post-treatment follow-up ranges from 34 to 50 weeks. For those seven patients, as of each patient's most recent reading, six of seven patients continue to have Factor VIII levels above 50%, as a percentage calculated based on the numbers of International Units per deciliter of plasma, and the seventh continues to be above 15%. The Company is expected to commission its commercial gene therapy manufacturing facility by mid-2017. The complimentary report on BMRN can be downloaded at:
Shares in Virginia headquartered CEL-SCI Corp. recorded a trading volume of 10.32 million shares at the close of the last trading session, which was above their three months average volume of 1.47 million shares. The stock ended the day 37.87% higher at $0.11. The Company's shares have advanced 2.27% in the last one month and 67.41% on an YTD basis. The stock is trading below its 50-day moving average by 38.52%. Furthermore, shares of CEL-SCI, which engages in the research and development of drugs and vaccines, have an RSI of 49.02.
On December 20th, 2016, CEL-SCI announced that it has received net proceeds of $3,702,760 and expects to receive the remaining $75,000 this week from its previously announced public offering of common stock and warrants, after deducting estimated placement agent discounts and commissions and estimated offering expenses payable by the Company. Visit us today and download our complete research report on CVM for free at:
New York-based Dipexium Pharmaceuticals Inc.'s shares finished Friday's session 3.33% lower at $1.45 with a total trading volume of 174,681 shares. The stock is trading below its 50-day moving average by 8.43%. Shares of the Company, which focuses on the development and commercialization of antibiotics in the US, have an RSI of 44.79.
On December 22nd, 2016, Dipexium Pharma and PLx Pharma Inc., a privately held late-stage specialty pharmaceutical company, announced that they have entered into a definitive agreement under which PLx Pharma will merge with a wholly-owned subsidiary of Dipexium in an all-stock transaction. Following closing, Dipexium will be renamed PLx Pharma Inc. Get free access to your technical report on DPRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA